Comparative Pharmacology
Head-to-head clinical analysis: COREG CR versus NADOLOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COREG CR versus NADOLOL.
COREG CR vs NADOLOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonselective beta-1, beta-2, and alpha-1 adrenergic receptor antagonist; no intrinsic sympathomimetic activity; reduces myocardial oxygen demand, decreases peripheral vascular resistance, and suppresses renin-angiotensin-aldosterone system.
Non-selective beta-adrenergic receptor antagonist (beta-blocker) that competitively blocks beta1 and beta2 receptors, reducing heart rate, myocardial contractility, and blood pressure.
Initial dose 20 mg orally once daily for patients with heart failure; may increase at 2-week intervals to a target dose of 80 mg once daily.
40 to 80 mg orally once daily, may be increased at 3-7 day intervals up to 240 mg once daily.
None Documented
None Documented
Clinical Note
moderateNadolol + Digitoxin
"Nadolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateNadolol + Deslanoside
"Nadolol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateNadolol + Acetyldigitoxin
"Nadolol may increase the bradycardic activities of Acetyldigitoxin."
Clinical Note
moderateNadolol + Ouabain
"Nadolol may increase the bradycardic activities of Ouabain."
Terminal elimination half-life is 7-10 hours; due to controlled-release formulation, effective half-life is prolonged to support once-daily dosing
Terminal elimination half-life: 14–24 hours (average 20 hours); prolonged in renal impairment (up to 45 hours) allowing once-daily dosing
Renal (16% unchanged, 60% as glucuronide conjugates), biliary/fecal (20%)
Renal (unchanged drug) 75-85%; fecal/biliary <5%
Category C
Category C
Beta-Blocker
Beta-Blocker